Bristol-Myers Squibb (BMY) stock shows potential for growth with recent FDA approval and strong oncology portfolio, but faces ...
Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...
Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...
Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other ...
Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...
Shares of Bristol Myers Squibb Co. BMY inched 0.67% higher to $53.96 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.90% ...
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia ...
Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel ...
On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...
Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-Myers Squibb (BMY – Research Report). The associated ...
Investor's Business Daily on MSN1d
Has Consumer Products Giant Bristol-Myers Squibb Kicked Into High Gear?A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback